Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002391 · ClinicalTrials.gov registry record · Phase 3
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002391 is a Phase 3 study that has completed, run by Glaxo Wellcome.
The verdict
NCT00002391, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, and neuropsychological or neurological changes. To assess the development of viral resistance and relative pharmacokinetics associated with each regimen.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002391
The ClinicalTrials.gov registry entry for NCT00002391 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002391 about?
NCT00002391 is a clinical study titled "The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs". To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, an...
What is the current status of trial NCT00002391?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002391?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002391?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.